Celgene Corporation Logo

E-mail this page: News Release

Efficacy and Safety Results from Second Phase III Trial (RADIANCE™ Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting

For security reasons, registration is required before you can use this feature.
* Indicates required field